TNF and rheumatoid arthritis: The significant response of CD4pos T cells from peripheral blood at day 0 of treatment and the relatively stable anti-CMV response over the course of treatment in our current study suggest (a) that anergy to anti-CMV Ags, if any, was not a prominent feature of RA patients; and (b) that anti-TNF treatments did not restore function from CD4pos T cells putatively engaged in anergy or in TNF-α-induced hyporesponsiveness [29].